Table 3.
Baseline Characteristics in Patients with LARC Following NCRT Stratified by Risk Group in Training and Validation Dataset
| Characteristics | Training Dataset | P value | Validation Dataset | P value | ||
|---|---|---|---|---|---|---|
| Low-Risk Group (n=85) | High-Risk Group (n=84) | Low-Risk Group (n=33) | High-Risk Group (n=54) | |||
| Sex (%) | 0.872 | 0.028 | ||||
| Male | 57 (67.1) | 55 (65.5) | 24 (72.7) | 26 (48.1) | ||
| Female | 28 (32.9) | 29 (34.5) | 9 (27.3) | 28(51.9) | ||
| Age (years) | 58.8 ± 10.8 | 55.3 ± 14.1 | 0.070 | 56.3 ± 9.8 | 59.8 ± 9.2 | 0.109 |
| ASA score (%) | 0.430 | 0.815 | ||||
| 1 | 56 (65.9) | 63(75.0) | 23(69.7) | 35(64.8) | ||
| 2 | 25 (29.4) | 18 (21.4) | 10 (30.3) | 19 (35.2) | ||
| 3 | 4 (4.7) | 3 (3.6) | 0(0.0) | 0(0.0) | ||
| Distance from the anal verge (cm) | 6.4 ± 2.9 | 6.7 ± 2.4 | 0.400 | 7.6 ± 2.5 | 6.3 ± 2.5 | 0.031 |
| Interval time between NCRT and surgery (weeks) | 8.4±1.9 | 8.5 ± 2.1 | 0.219 | 8.7±1.7 | 8.2 ± 1.4 | 0.158 |
| Pre-NCRT cT stage (%) | 0.335 | 0.573 | ||||
| T2 | 4 (4.7) | 1(1.2) | 0(0.0) | 1(1.9) | ||
| T3 | 34(40.0) | 31 (36.9) | 10(30.3) | 20 (37.0) | ||
| T4 | 47 (55.3) | 52 (61.9) | 23 (69.7) | 33 (61.1) | ||
| Pre-NCRT cN stage (%) | 0.794 | 0.363 | ||||
| N0 | 9 (10.6) | 7 (8.3) | 3 (9.4) | 2 (3.7) | ||
| N+ | 76 (89.4) | 77(91.7) | 30 (90.9) | 52 (96.3) | ||
| Pre-NCRT CEA (%) | 0.063 | 0.021 | ||||
| <5.0 ng/mL | 54 (63.5) | 41 (48.8) | 57 (64.8) | 38 (46.9) | ||
| ≥5.0 ng/mL | 31 (35.5) | 43 (51.2) | 31 (35.2) | 43 (53.1) | ||
| Post-surgery CEA (%) | 0.314 | 0.226 | ||||
| <5.0 ng/mL | 73 (85.9) | 67 (79.8) | 76 (86.4) | 64 (79.0) | ||
| ≥5.0 ng/mL | 12 (14.1) | 17 (20.2) | 12 (13.6) | 17 (21.0) | ||
Abbreviations: LARC, locally advanced rectal cancer; NCRT, neoadjuvant chemoradiotherapy; ASA, American Society of Anesthesiologists; CEA, carcinoembryonic antigen.